{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:51:04Z","timestamp":1790175064920,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The hypothesis that increased ADAMTS13 (a disintegrin and metalloprotease with thrombospondin repeats) activity or increased susceptibility of von Willebrand factor (VWF) to proteolysis by ADAMTS13 may underlie type I von Willebrand disease (VWD) in some patients was investigated. Plasma from 4 patients with type I VWD was cryoprecipitated. ADAMTS13 activity in the VWF-poor cryodepleted fraction was assessed by incubation with purified VWF; susceptibility to proteolysis of the VWF in the VWF-rich cryoprecipitate was assessed by incubation with a normal, group O cryodepleted plasma. ADAMTS13 activity was similar in all 4 type I VWD cryodepleted plasmas and comparable to a normal control plasma. In contrast, the VWF of one patient showed increased susceptibility to proteolysis by ADAMTS13. Investigation of additional family members indicated that increased susceptibility was heritable, but it did not track uniquely with type I VWD. Sequence analysis of VWF exon 28 indicated that increased susceptibility to proteolysis tracked with the \u201cG\u201d allele of the A\/G polymorphism at position 24\/1282, encoding the amino acid polymorphism Tyr\/Cys1584 (\u201cG\u201d = Cys1584). A prospective study of 200 individuals yielded 2 Tyr\/Cys1584 heterozygotes; for both, plasma VWF showed increased susceptibility to proteolysis. The finding that an amino acid polymorphism in VWF may influence susceptibility to ADAMTS13 has potentially significant implications in diverse areas. (Blood. 2004;103:941-947)<\/jats:p>","DOI":"10.1182\/blood-2003-05-1505","type":"journal-article","created":{"date-parts":[[2003,10,7]],"date-time":"2003-10-07T00:16:34Z","timestamp":1065485794000},"page":"941-947","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13"],"prefix":"10.1182","volume":"103","author":[{"given":"Derrick John","family":"Bowen","sequence":"first","affiliation":[{"name":"From the Department of Hematology, University of Wales College of Medicine, Heath Park, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter William","family":"Collins","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, University of Wales College of Medicine, Heath Park, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021221412221900_REF1","unstructured":"Ruggeri ZM. Structure and biosynthesis of von Willebrand factor. In: Ruggeri ZM, ed. Von Willebrand Factor and the Mechanisms of Platelet Function. Berlin, Germany: Springer; 1998: 33-77."},{"key":"2020021221412221900_REF2","doi-asserted-by":"crossref","unstructured":"Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri Z. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A. 1990;87: 6306-6310.","DOI":"10.1073\/pnas.87.16.6306"},{"key":"2020021221412221900_REF3","doi-asserted-by":"crossref","unstructured":"Furlan M, Robles R, La\u0308mmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87: 4223-4234.","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223"},{"key":"2020021221412221900_REF4","doi-asserted-by":"crossref","unstructured":"Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin and collagen and characterization of its three distinct functional sites. J Biol Chem. 1989;264: 17361-17367.","DOI":"10.1016\/S0021-9258(18)71501-9"},{"key":"2020021221412221900_REF5","doi-asserted-by":"crossref","unstructured":"Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor with collagen. J Biol Chem. 1995;270: 10822-10827.","DOI":"10.1074\/jbc.270.18.10822"},{"key":"2020021221412221900_REF6","doi-asserted-by":"crossref","unstructured":"Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry. 1986;25: 3171-3184.","DOI":"10.1021\/bi00359a015"},{"key":"2020021221412221900_REF7","doi-asserted-by":"crossref","unstructured":"Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413: 488-494.","DOI":"10.1038\/35097008"},{"key":"2020021221412221900_REF8","doi-asserted-by":"crossref","unstructured":"Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339: 1578-1584.","DOI":"10.1056\/NEJM199811263392202"},{"key":"2020021221412221900_","doi-asserted-by":"crossref","unstructured":"Tsai HM, Lian CY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New Engl J Med. 1998;339: 1585-1594.","DOI":"10.1056\/NEJM199811263392203"},{"key":"2020021221412221900_REF10","doi-asserted-by":"crossref","unstructured":"Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol. 2000;65: 251-255.","DOI":"10.1002\/1096-8652(200011)65:3<251::AID-AJH13>3.0.CO;2-2"},{"key":"2020021221412221900_REF11","doi-asserted-by":"crossref","unstructured":"Gerritsen HE, Turecek PL, Schwarz HP, La\u0308mmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF. Thromb Haemost. 1999;82: 1386-1389.","DOI":"10.1055\/s-0037-1614780"},{"key":"2020021221412221900_REF12","doi-asserted-by":"crossref","unstructured":"Furlan M, Lammle B. Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. Semin Thromb Haemost. 2002;28: 167-172.","DOI":"10.1055\/s-2002-27819"},{"key":"2020021221412221900_REF13","doi-asserted-by":"crossref","unstructured":"Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalised to antigen levels for a rapid diagnosis of type 2 von Willebrand disease. Thromb Haemost. 2000;84: 1127-1128.","DOI":"10.1055\/s-0037-1614188"},{"key":"2020021221412221900_REF14","doi-asserted-by":"crossref","unstructured":"Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in type IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individuals oligomers (types IIC, IID, and IIE). J Clin Invest. 1986;77: 947-951.","DOI":"10.1172\/JCI112394"},{"key":"2020021221412221900_REF15","doi-asserted-by":"crossref","unstructured":"Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 2003;1: 33-40.","DOI":"10.1046\/j.1538-7836.2003.00007.x"},{"key":"2020021221412221900_REF16","doi-asserted-by":"crossref","unstructured":"Raines G, Aumann H, Sykes S, Street A. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gels. Thromb Res. 1990;60: 201-212.","DOI":"10.1016\/0049-3848(90)90181-B"},{"key":"2020021221412221900_REF17","unstructured":"Short PE, Williams CE, Picken AM, Hill FG. Factor VIII related antigen: an improved enzyme immunoassay. Med Lab Sci. 1982;39: 351-355."},{"key":"2020021221412221900_REF18","unstructured":"McFarlane DE, Stibbe J, Kibbey EP, Zucher MB, Grant R, McPherson J. A method for assaying von Willebrand factor (ristocetin co-factor). Thromb Diath Haemorrhagic. 1975;34: 306-308."},{"key":"2020021221412221900_REF19","doi-asserted-by":"crossref","unstructured":"Bowen DJ, Standen GR, Granville S, Bowley S, Wood NA, Bidwell J. Genetic diagnosis of factor V Leiden using heteroduplex technology. Thromb Haemost. 1997;77: 119-22.","DOI":"10.1055\/s-0038-1655917"},{"key":"2020021221412221900_REF20","doi-asserted-by":"crossref","unstructured":"Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem. 1989;264: 19514-19527.","DOI":"10.1016\/S0021-9258(19)47144-5"},{"key":"2020021221412221900_REF21","doi-asserted-by":"crossref","unstructured":"Mancuso DJ, Tuley EA, Westfield LA, et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry. 1991;30: 253-269.","DOI":"10.1021\/bi00215a036"},{"key":"2020021221412221900_REF22","doi-asserted-by":"crossref","unstructured":"Dong J, Moake JL. Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100: 4033-4039.","DOI":"10.1182\/blood-2002-05-1401"},{"key":"2020021221412221900_REF23","doi-asserted-by":"crossref","unstructured":"Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69: 1691-1695.","DOI":"10.1182\/blood.V69.6.1691.1691"},{"key":"2020021221412221900_REF24","doi-asserted-by":"crossref","unstructured":"Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII\/von Willebrand factor in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol. 1981;47: 283-293.","DOI":"10.1111\/j.1365-2141.1981.tb02789.x"},{"key":"2020021221412221900_REF25","doi-asserted-by":"crossref","unstructured":"Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor post-DDAVP in type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost. 2003;1: 1714-1717.","DOI":"10.1046\/j.1538-7836.2003.00359.x"},{"key":"2020021221412221900_REF26","unstructured":"Millar CM, Riddell AF, Bell RJ, et al. Study of VWF antigen clearance in patients with type 1 von Willebrand disease and reporting of a familial tendency [abstract]. Br J Haematol. 2003;121(suppl 1): 21."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/3\/941\/1694451\/zh800304000941.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/3\/941\/1694451\/zh800304000941.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T18:09:53Z","timestamp":1623434993000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/3\/941\/17194\/An-amino-acid-polymorphism-in-von-Willebrand"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-05-1505","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,1]]}}}